A study published in PubMed explores the use of salvage tacrolimus therapy for patients with steroid-refractory immune-related adverse event-associated sclerosing cholangitis. This research highlights a potential treatment avenue for a challenging condition often seen in cancer immunotherapy.
salvage tacrolimus therapy for steroid refractory immune related adverse event associated sclerosing cholangitis
Original title: “Salvage tacrolimus therapy for steroid-refractory immune-related adverse event-associated sclerosing cholangitis.”